Drugs / Measles, mumps, and rubella (MMR) vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01436396 Background | Sep 2011 → Sep 2013 | Dengue hemorrhagic fever, yellow fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella (MMR) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01436396 ↗ |
| Modality | Vaccine | “Measles, mumps, and rubella (MMR) vaccine” NCT01436396 ↗ |
| Route | Subcutaneous | “0.5 mL, subcutaneous at age 12 to 13 months.” NCT01436396 ↗ |